Evaluation of the Treatment Efficacy of Generic Enrofloxacin Compared to Pioneer Enrofloxacin for First Treatment of Naturally Occurring Bovine Respiratory Disease in a Commercial Feedlot -- Sponsored by Virbac

Have You Herd? AABP PodCasts

AABP Executive Director Dr. Fred Gingrich is joined by Dr. Miles Theurer from Veterinary Research and Consulting Services. Theurer was the lead author of the paper “Evaluation of the treatment efficacy of generic enrofloxacin compared to pioneer enrofloxacin for first treatment of naturally occurring bovine respiratory disease in a commercial feedlot” published in The Bovine Practitioner Volume 57 Number 2. This episode is sponsored by Virbac. After more than 50 years of helping animals around the world, Virbac wants to emphasize that they are here for you, committed to your growth and that of your customers for the long haul. For more information on Virbac or their products, visit https://vet-us.virbac.com/cattle.

Theurer discusses the reasons that a large clinical trial comparing a generic product to the pioneer product in a field setting can assist veterinarians in making treatment decisions when recommending animal health products to their clients. Theurer walks us through the objectives and methods of the paper. Results of this paper did not find any significant differences in health outcomes evaluated for first treatment of BRD with the two products. He also discusses some of the differences identified between traditional beef breeds enrolled in the study and dairy-beef crosses which is an opportunity for future research.

Theurer discusses his role as an associate editor for The Bovine Practitioner and encourages researchers to submit clinically relevant research to the journal. The journal is intended to provide research relevant to the practicing cattle veterinarian and is available open-access with no publication fees. The submission and review process is managed online. Find the journal at this link.
Theurer, M. E., Fox, T., Newberry, J. R., & Payot, F. (2023). Evaluation of the treatment efficacy of generic enrofloxacin compared to pioneer enrofloxacin for first treatment of naturally occurring bovine respiratory disease in a commercial feedlot. The Bovine Practitioner, 57(2), 29–35. https://doi.org/10.21423/bovine-vol27no2p29-35

Product label and safety information for Tenotryl located on this page.

CATTLE IMPORTANT SAFETY INFORMATION

Tenotryl™ (enrofloxacin) 100 mg/ml Antimicrobial Injectable Solution: Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in the calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not exceed a 20 mL dose per injection site. Federal (USA) law prohibits the extra-label use of this drug in food producing animals.